A polymorphism in the resistin gene promoter is related to increased C-reactive protein levels in patients with coronary artery disease

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 11, 2007, Pages 1471-1475

  Tang, Na Ping ^a   Wang, Lian Sheng ^a   Yang, Li ^a   Zhou, Bo ^a   Gu, Hai Juan ^a   Sun, Qing Min ^a   Cong, Ri Hong ^a   Zhu, Huai Jun ^a   Wang, Bin ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

C reactive protein; Coronary artery disease; Polymorphism; Resistin

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; LIPID; RESISTIN;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE DETECTION; HUMAN; LIPID BLOOD LEVEL; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL ANALYSIS;

AGED; BASE SEQUENCE; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; DNA PRIMERS; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RESISTIN;

EID: 35648957319     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.308     Document Type: Article

References (32)

1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
2. Angiolillo DJ, Biasucci LM, Liuzzo G, Crea F. Inflammation in acute coronary syndromes: mechanisms and clinical implications. Rev Esp Cardiol 2004;57:433-46.
3. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9.
4. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
5. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-12.
6. Kim KH, Lee K, Moon YS, Sul HS. A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem 2001;276:11252-6.
7. Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, et al. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 2000;19:4046-55.
8. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005;174:5789-95.
9. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005;111:932-9.
10. Al-Daghri N, Chetty R, McTernan PG, Al-Rubean K, Al-Attas O, Jones AF, et al. Serum resistin is associated with C-reactive protein & LDL cholesterol in type 2 diabetes and coronary artery disease in a Saudi population. Cardiovasc Diabetol 2005;4:10.
11. Pilz S, Weihrauch G, Seelhorst U, Wellnitz B, Winkelmann BR, Boehm BO, et al. Implications of resistin plasma levels in subjects undergoing coronary angiography. Clin Endocrinol (Oxf) 2007;66:380-6.
12. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004;27:2450-7.
13. Bo S, Gambino R, Pagani A, Guidi S, Gentile L, Cassader M, et al. Relationships between human serum resistin, inflammatory markers and insulin resistance. Int J Obes (Lond) 2005;29:1315-20.
14. Migita K, Maeda Y, Miyashita T, Kimura H, Nakamura M, Ishibashi H, et al. The serum levels of resistin in rheumatoid arthritis patients. Clin Exp Rheumatol 2006;24:698-701.
15. Rajala MW, Lin Y, Ranalletta M, Yang XM, Qian H, Gingerich R, et al. Cell type-specific expression and coregulation of murine resistin and resistin-like molecule-alpha in adipose tissue. Mol Endocrinol 2002;16:1920-30.
16. Lu SC, Shieh WY, Chen CY, Hsu SC, Chen HL. Lipopolysaccharide increases resistin gene expression in vivo and in vitro. FEBS Lett 2002;530:158-62.
17. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Tumor necrosis factor alpha is a negative regulator of resistin gene expression and secretion in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2001;288:1027-31.
18. Cao H, Hegele RA. Single nucleotide polymorphisms of the resistin (RSTN) gene. J Hum Genet 2001;46:553-5.
19. Engert JC, Vohl MC, Williams SM, Lepage P, Loredo-Osti JC, Faith J, et al. 5′ flanking variants of resistin are associated with obesity. Diabetes 2002;51:1629-34.
20. Osawa H, Yamada K, Onuma H, Murakami A, Ochi M, Kawata H, et al. The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. Am J Hum Genet 2004;75:678-86.
21. Osawa H, Onuma H, Ochi M, Murakami A, Yamauchi J, Takasuka T, et al. Resistin SNP-420 determines its monocyte mRNA and serum levels inducing type 2 diabetes. Biochem Biophys Res Commun 2005;335:596-602.
22. Cho YM, Youn BS, Chung SS, Kim KW, Lee HK, Yu KY, et al. Common genetic polymorphisms in the promoter of resistin gene are major determinants of plasma resistin concentrations in humans. Diabetologia 2004;47:559-65.
23. Azuma K, Oguchi S, Matsubara Y, Mamizuka T, Murata M, Kikuchi H, et al. Novel resistin promoter polymorphisms: association with serum resistin level in Japanese obese individuals. Horm Metab Res 2004;36:564-70.
24. Kunnari A, Ukkola O, Kesaniemi YA. Resistin polymorphisms are associated with cerebrovascular disease in Finnish type 2 diabetic patients. Diabet Med 2005;22:583-9.
25. Wang B, Pan J, Wang L, Zhu H, Yu R, Zou Y. Associations of plasma 8-isoprostane levels with the presence and extent of coronary stenosis in patients with coronary artery disease. Atherosclerosis 2006;184:425-30.
26. Zhu H, Yang L, Zhou B, Yu R, Tang N, Wang B. Myeloperoxidase G-463A polymorphism and the risk of gastric cancer: a case-control study. Carcinogenesis 2006;27:2491-6.
27. Worns MA, Victor A, Galle PR, Hohler T. Genetic and environmental contributions to plasma C-reactive protein and interleukin-6 levels - a study in twins. Genes Immun 2006;7:600-5.
28. de Maat MP, Bladbjerg EM, Hjelmborg JB, Bathum L, Jespersen J, Christensen K. Genetic influence on inflammation variables in the elderly. Arterioscler Thromb Vasc Biol 2004;24:2168-73.
29. Bernardo E, Angiolillo DJ, Ramirez C, Cavallari U, Trabetti E, Sabate M, et al. Influence of the CD14 C260T promoter polymorphism on C-reactive protein levels in patients with coronary artery disease. Am J Cardiol 2006;98:1182-4.
30. Lekakis JP, Ikonomidis I, Tsibida M, Protogerou A, Papada A, Papapanagiotou A, et al. Genetic variations of the endothelial nitric oxide synthase gene are related to increased levels of C-reactive protein and macrophagecolony stimulating-factor in patients with coronary artery disease. Thromb Haemost 2006;96:520-8.
31. Maachi M, Pieroni L, Bruckert E, Jardel C, Fellahi S, Hainque B, et al. Systemic low-grade inflammation is related to both circulating and adipose tissue TNFalpha, leptin and IL-6 levels in obese women. Int J Obes Relat Metab Disord 2004;28:993-7.
32. Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004;314:415-9.